yahoo_financeOriginal article
Seres Therapeutics’ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study
Data ReadoutpositiveSER-155Positive
AI Analysis
Summary
Seres Therapeutics announced that SER-155 achieved an 80% response rate in a cancer immunotherapy gastrointestinal toxicity study. The positive clinical data demonstrates efficacy in managing a known side effect of cancer immunotherapy.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
80% response rate in GI toxicity study
Importance:6/10
Sentiment:
0.70
SER-155cancer immunotherapyGI toxicityclinical trialresponse rate
Related Companies
Read the original article
Published by yahoo_finance on July 10, 2026 6:02 PM